Aspira Women’s Health reports Q2 EPS (28c), consensus (55c)

Reports Q3 revenue $2.5M, consensus $2.8M…”Our optimism continues to grow as we achieved sustained improvement across the company this quarter. OvaWatchSM test volume grew 80% in its second full quarter, contributing 14% of the total 6,289 OvaSuite tests performed. Test volume per field representative continues to improve, growing more than 69% to 598 for the six months ended June 30, 2023, as a result of the ongoing strategic refresh of our commercial programs,” said Nicole Sandford, Aspira’s President and Chief Executive Officer. “As we look to the second half of the year, our focus is on the successful expansion of OvaWatch as a longitudinal monitoring test, and the launch of our EndoCheck blood test. Both efforts are progressing as planned.” Sandford continued, “Cash used in operations was $3.4 million, a decrease of nearly 46% compared to the second quarter of last year. Fiscal discipline, combined with the forgiveness of $1 million of debt, and an equity raise in July that brought in net proceeds of $4.3 million, has strengthened our balance sheet and sets us up for a successful second half.” The company